JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Neal Flomenberg, Chief Scientific Officer and Global R&D Lead at Tevogen Bio Holdings Inc. (NASDAQ:TVGN), has recently sold shares of the company. According to a recent SEC filing, Flomenberg sold 232,968 shares of common stock on March 12, realizing a total of approximately $253,935. The shares were sold at a weighted average price of $1.09 per share, with the transaction prices ranging from $1.05 to $1.12.
These stock sales were conducted to satisfy tax obligations associated with the vesting and settlement of restricted stock units, as noted in the filing. Following the transaction, Flomenberg retains direct ownership of 3,595,608 shares of Tevogen Bio. According to InvestingPro analysis, the company currently shows weak financial health indicators, with short-term obligations exceeding liquid assets. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper insight into TVGN’s performance and valuation.
In other recent news, Tevogen Bio has filed a new patent application for its T cell vaccine technology with the U.S. Patent and Trademark Office. This innovative approach focuses on stimulating a T cell response to the entire viral genome, aiming to address challenges posed by viral mutations. The company has reported positive safety data from its proof-of-concept clinical trial and maintains key intellectual property assets. Additionally, Tevogen Bio has announced that this development will not impact the previously projected $1 billion topline forecasts for its Oncology and Specialty Care divisions.
Boral (OTC:BOALY) Capital recently assigned a Buy rating to Tevogen Bio, with a price target of $10.00, reflecting optimism about the company’s innovative cell therapy platform. The company’s lead product, TVGN-489, is in development to provide targeted immune protection for high-risk COVID-19 patients. Furthermore, Tevogen Bio has expanded its collaboration with Microsoft (NASDAQ:MSFT), utilizing AI and cloud capabilities to advance its PredicTcell technology. This partnership is expected to enhance the development of predictive precision T-cell targeting solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.